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Despite late complications related to radiation therapy, RT 
remains a standard component of treatment among pediatric 
patients.                                                                               
The current aim of many pediatric clinical trials is to reduce 
dose and volume of irradiation to decrease side effects 
without affecting the rate of local control using multi-
modality treatment. 
Recent advances in radiotherapy technology contribute also 
to improve therapeutic ratio thanks to better conformal dose 
distribution and avoidance of surrounding critical structures. 
Integration of multimodal imaging in target delineation, use 
of CT for treatment planning (3D conformal radiation 
therapy) and immobilization devices have significantly 
decreased clinical and planning target volume margins. 
Intensity modulated radiation therapy could be particularly 
useful in cases of complex and large volume closed to critical 
structures.  While high dose to neighboring structures can be 
selectively decreased by the means of IMRT, low dose is 
raised in the rest of the body with theoretical increased risk 
of secondary malignancies or unexpected toxicities related to 
irradiation of very sensitive organs at risk located at distance 
of target volume. Number of prospective studies comparing 
IMRT to 3D CRT is low. However available data suggest that 
IMRT provided local control equivalent to 3D CRT with 
favorable short term toxicity profile and reduction of some 
sequelae.  No excess of second tumor is described but follow-
up is still limited.   
Concerning strategies for management of internal target 
movement due to respiratory motion, the more widespread 
modality in pediatric radiotherapy is 4-dimensional CT for 
radiation. Other techniques such as active breathing control 
or respiratory gating is not widely widespread because their 
use is conditioned by collaboration ability and patient age. 
Up to now stereotactic radiation therapy has been mainly 
used in childhood for intracranial benign disease by 
neurosurgeon. However development of non-invasive 
repositioning system and LINAC dedicated to stereotactic 
irradiation gives the opportunity of hypofractionated 
treatment of metastasis or recurrence in previously 
irradiated field with minimal impact of quality of live in 
palliative setting.   
With high precision techniques, reproducibility in daily set-up 
becomes more critical to prevent geographic misses and 
image-guided RT (IGRT) has become a common practice of 
care for children as for the adults. One of the most applied 
IGRT technique is cone-beam computed tomography (CBCT). 
A limitation in use of CBCT among pediatric population is the 
extra dose deposit to critical structures witch is higher in 
children than in adults. Because of potential of yielding a 
secondary cancer at long term, it is essential to adapt 
scanning protocol when CBCT is applied to pediatric cancer 
patients routinely. 
   
SP-0307   
131-iodine meta-iodobenzylguanidine molecular 
radiotherapy for neuroblastoma 
M.N. Gaze1 
1University College London Hospitals NHS Foundation Trust, 
Clinical Oncology, London, United Kingdom  
 
Neuroblastoma, predominantly a cancer of young children, is 
derived from the sympathetic nervous system. Patients are 
risk-stratified by age, stage and molecular pathology to guide 
treatment and predict outcome. High-risk neuroblastoma, 
usually defined as metastatic disease over the age of one 
year, or the presence of MYCN amplification, is the most 
common risk group, and carries a high mortality. New and 
better treatments are necessary.  
Neuroblastoma cells usually express the Noradrenaline 
Transporter (NAT) molecule which takes up meta-
Iodobenzylguanidine (mIBG), a noradenaline analogue. 
Labelled with iodine-123 for imaging or iodine-131 for 
therapy, mIBG has been used clinically in neuroblastoma and 
other NAT expressing tumours for about 30 years. Semi-
quantitative scoring of 123I-mIBG scintigraphy has become the 
gold standard imaging technique for staging, response 
assessment and follow-up of patients with neuroblastoma. 
Molecular radiotherapy with 131I-mIBG is an attractive 
treatment option for children with high-risk metastatic 
neuroblastoma because (1) the disease is disseminated, 
making local therapies alone inadequate, (2)  123I-mIBG 
scintigraphy is a predictive imaging biomarker for avid 
accumulation of 131I-mIBG in the primary tumour and 
metastatic sites, and (3) neuroblastoma is often relatively 
radiosensitive meaning impressive responses to treatment 
can be seen. 
Initially used in relapsed patients with only palliative intent, 
the use of 131I-mIBG therapy has in recent years has been 
brought forward in the course of the illness as either a first- 
or second-line strategy with the aim of increasing the 
prospects for cure. Further research efforts, especially 
randomised trials, are however needed to demonstrate its 
true value. 
The principal and therefore dose-limiting toxicity of 131I-mIBG 
therapy is haematological. The whole body absorbed 
radiation dose correlates with the haematological toxicity, 
and so whole body dosimetry can be used, in conjunction 
with peripheral blood stem cell support, to allow the use 
of higher administered activities than were previously 
considered safe. There is laboratory evidence to support the 
hypothesis that improvements in outcome may possibly be 
achieved by the simultaneous use of radiosensitising drugs 
such as topoisomerase I inhibitors. Initial clinical experience 
has been published, and clinical trials using irinotecan and 
topotecan in conjunction with 131I-mIBG are in progress or 
planned to evaluate this approach further. 
There are practical challenges when young children need to 
receive high administered activities of 131I-mIBG. The use of 
comforters and carers, usually the child's parents, is an 
essential addition to medical and nursing care. All individuals 
involved need to appreciate the risks, and be trained in 
sensible radiation protection precautions. 
Other forms of molecular radiotherapy for neuroblastoma are 
being investigated, particularly peptide receptor radionuclide 
therapy targeting the somatostatin receptor, using 
radiolabelled somatostatin analogues. Examples are 90Y-
DOTATOC and 177Lu-DOTATATE. These are not necessarily 
alternatives to 131I-mIBG therapy. Both immunohistochemical 
studies of NAT and somatostatin receptor expression in 
neuroblastoma tissue, and imaging comparisons of 123I-mIBG 
scintigraphy and 68Ga-DOTATATE PET/CT demonstrate a 
heterogeneity of appearances suggesting that they may be 
complementary. 
This presentation reviews the published evidence in relation 
to 131I-mIBG therapy for neuroblastoma, and describes the 
plans to further evaluate its place through clinical trials in 
the context of other systemic treatments for this hard-to-
cure disease. 
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